Company intelligence / Profile preview

Sedana Medical

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Sedana Medical has successfully commercialized its inhaled sedation system—combining the medical device Sedaconda ACD and the pharmaceutical product Sedaconda (isoflurane)—for use in mechanically ventilated ICU patients. Pivotal clinical studies have established efficacy and safety, supporting regulatory approvals and market adoption across >40 countries. Ongoing clinical programs aim to expand usage.

Therapeutic areas: OtherNeurology
Modalities: Device (Anaesthetic conserving device)Small molecule (isoflurane)
Industry: Biotech

Drug pipeline

1 asset

isoflurane

Commercial

Indications: Sedation in intensive care

Partnerships

Distribution partnerships with external distributors across Europe, Asia, Australia, Canada, South America, Central AmericaPartnership with Device Technologies in Australia/New Zealand

Beyond the preview

Go deeper on Sedana Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sedana Medical.

Explore the full profile